TXMD Relative Valuation
TXMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TXMD is overvalued; if below, it's undervalued.
Historical Valuation
TherapeuticsMD Inc (TXMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.19. The fair price of TherapeuticsMD Inc (TXMD) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.60
Fair
10.06
PE
1Y
3Y
5Y
Trailing
Forward
0.13
EV/EBITDA
TherapeuticsMD Inc. (TXMD) has a current EV/EBITDA of 0.13. The 5-year average EV/EBITDA is -1.31. The thresholds are as follows: Strongly Undervalued below -8.02, Undervalued between -8.02 and -4.67, Fairly Valued between 2.04 and -4.67, Overvalued between 2.04 and 5.39, and Strongly Overvalued above 5.39. The current Forward EV/EBITDA of 0.13 falls within the Historic Trend Line -Fairly Valued range.
7.73
EV/EBIT
TherapeuticsMD Inc. (TXMD) has a current EV/EBIT of 7.73. The 5-year average EV/EBIT is -2.74. The thresholds are as follows: Strongly Undervalued below -26.08, Undervalued between -26.08 and -14.41, Fairly Valued between 8.94 and -14.41, Overvalued between 8.94 and 20.61, and Strongly Overvalued above 20.61. The current Forward EV/EBIT of 7.73 falls within the Historic Trend Line -Fairly Valued range.
2.00
PS
TherapeuticsMD Inc. (TXMD) has a current PS of 2.00. The 5-year average PS is 3.99. The thresholds are as follows: Strongly Undervalued below -5.94, Undervalued between -5.94 and -0.97, Fairly Valued between 8.95 and -0.97, Overvalued between 8.95 and 13.92, and Strongly Overvalued above 13.92. The current Forward PS of 2.00 falls within the Historic Trend Line -Fairly Valued range.
1.53
P/OCF
TherapeuticsMD Inc. (TXMD) has a current P/OCF of 1.53. The 5-year average P/OCF is -1.16. The thresholds are as follows: Strongly Undervalued below -7.42, Undervalued between -7.42 and -4.29, Fairly Valued between 1.97 and -4.29, Overvalued between 1.97 and 5.11, and Strongly Overvalued above 5.11. The current Forward P/OCF of 1.53 falls within the Historic Trend Line -Fairly Valued range.
12.27
P/FCF
TherapeuticsMD Inc. (TXMD) has a current P/FCF of 12.27. The 5-year average P/FCF is 1.75. The thresholds are as follows: Strongly Undervalued below -11.31, Undervalued between -11.31 and -4.78, Fairly Valued between 8.28 and -4.78, Overvalued between 8.28 and 14.81, and Strongly Overvalued above 14.81. The current Forward P/FCF of 12.27 falls within the Overvalued range.
TherapeuticsMD Inc (TXMD) has a current Price-to-Book (P/B) ratio of 0.67. Compared to its 3-year average P/B ratio of 0.77 , the current P/B ratio is approximately -13.05% higher. Relative to its 5-year average P/B ratio of -3.19, the current P/B ratio is about -121.02% higher. TherapeuticsMD Inc (TXMD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -104.57%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -83.94% , the current FCF yield is about -100.00% lower.
0.68
P/B
Median3y
0.77
Median5y
-3.19
11.24
FCF Yield
Median3y
-104.57
Median5y
-83.94
Competitors Valuation Multiple
The average P/S ratio for TXMD's competitors is 0.00, providing a benchmark for relative valuation. TherapeuticsMD Inc Corp (TXMD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 43.33%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of TXMD increased by 87.21% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 101.97 to 254.95.
The secondary factor is the Revenue Growth, contributed 43.33%to the performance.
Overall, the performance of TXMD in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is TherapeuticsMD Inc (TXMD) currently overvalued or undervalued?
What is TherapeuticsMD Inc (TXMD) fair value?
How does TXMD's valuation metrics compare to the industry average?
What is the current P/B ratio for TherapeuticsMD Inc (TXMD) as of Dec 05 2025?
What is the current FCF Yield for TherapeuticsMD Inc (TXMD) as of Dec 05 2025?
What is the current Forward P/E ratio for TherapeuticsMD Inc (TXMD) as of Dec 05 2025?